Ketamine as an Adjuvant in External Oblique Intercostal Plane Block for Post Thoracotomy Pain

NCT07138781 | Completed

• 1 other identifier: 36264PR1282/7/25
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to evaluate the role of ketamine as an adjuvant in external oblique intercostal plane block for post thoracotomy pain.

Conditions

Adjuvant; Thoracotomy; Pain; Ketamine; External Oblique Intercostal Plane Block

Outcome Measures

Primary Outcomes (1)

• Time to the 1st rescue analgesia

  Time to the first request for the rescue analgesia will be recorded from end of surgery to first dose of morphine administrated.

  48 hours postoperatively

Secondary Outcomes (6)

• Intraoperative fentanyl consumption

  Intraoperatively

• Total morphine consumption

  48 hours postoperatively

• Degree of pain

  48 hours postoperatively

• Mean arterial pressure

  Till the end of surgery (Up to 2 hours)

• Heart rate

  Till the end of surgery (Up to 2 hours)

Study Arms (2)

Group K

EXPERIMENTAL

Patients will receive 29 ml bupivacaine 0.25% + 1 ml ketamine (50 mg) as a study group.

Drug: Ketamine

Group C

ACTIVE COMPARATOR

Patients will receive 29 ml bupivacaine 0.25% + 1 ml saline as a control group.

Drug: 29 ml bupivacaine 0.25% + 1 ml saline

Interventions

Ketamine DRUG

Patients will receive 29 ml bupivacaine 0.25% + 1 ml ketamine (50 mg).

Group K

29 ml bupivacaine 0.25% + 1 ml saline DRUG

Patients will receive 29 ml of bupivacaine 0.25% + 1 ml of saline.

Group C

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years.
• Both sexes.
• American Society of Anesthesiology (ASA) physical status I-III.
• Scheduled for open thoracotomy.

You may not qualify if:

• Patients with neurological or intellectual disability.
• Infection at the injection site.
• Opioid addiction.
• Allergic reaction to local anesthetics.
• Coagulation abnormalities.
• Drug abuse.
• Pregnancy.
• Severe liver and/or renal failure.
• Severe cardiovascular problems.

Sponsors & Collaborators

• Tanta University: lead

Study Sites (1)

Tanta University

Tanta, El-Gharbia, 31527, Egypt

Location

MeSH Terms

Conditions

Pain

Interventions

Ketamine; Bupivacaine; Sodium Chloride

Condition Hierarchy (Ancestors)

Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Cyclohexanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Anilides; Amides; Aniline Compounds; Amines; Chlorides; Hydrochloric Acid; Chlorine Compounds; Inorganic Chemicals; Sodium Compounds

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.

Study Record Dates

• First Submitted: August 17, 2025
• First Posted: August 24, 2025
• Study Start: August 23, 2025
• Primary Completion: February 17, 2026
• Study Completion: February 17, 2026
• Last Updated: February 27, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)